US 11,725,060 B2
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
David Bienvenue, Seattle, WA (US); Gabriela Hernandez-Hoyos, Seattle, WA (US); Lynda Misher, Seattle, WA (US); Danielle Van Citters, Seattle, WA (US); Peter Ellmark, Lund (SE); Anna Sall, Lund (SE); Christina Furebring, Lund (SE); Laura von Schantz, Lund (SE); Sara Fritzell, Lund (SE); and Laura Varas, Lund (SE)
Assigned to Aptevo Reserch and Development LLC, Seattle, WA (US); and Alligator Bioscience AB, Lund (SE)
Appl. No. 16/632,144
Filed by Aptevo Research and Development, LLC, Seattle, WA (US); and Alligator Bioscience AB, Lund (SE)
PCT Filed Jul. 20, 2018, PCT No. PCT/EP2018/069850
§ 371(c)(1), (2) Date Jan. 17, 2020,
PCT Pub. No. WO2019/016402, PCT Pub. Date Jan. 24, 2019.
Claims priority of provisional application 62/648,072, filed on Mar. 26, 2018.
Claims priority of provisional application 62/575,820, filed on Oct. 23, 2017.
Claims priority of provisional application 62/535,107, filed on Jul. 20, 2017.
Prior Publication US 2020/0223933 A1, Jul. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); C12N 15/00 (2006.01); C12N 15/13 (2006.01); C12N 15/62 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); C12N 15/63 (2006.01); C12N 5/10 (2006.01)
CPC C07K 16/30 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 38/00 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5152 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 2800/00 (2013.01)] 24 Claims
 
1. A multispecific polypeptide comprising a first scFv domain and a second scFv domain, wherein the first and second scFv domains are linked together by a binding domain linker or a binding domain linker and an immunoglobulin Fc domain, wherein the immunoglobulin Fc domain comprises a hinge region and an immunoglobulin constant region; and
wherein the first scFv domain specifically binds to human 5T4 and comprises:
(i) an immunoglobulin heavy chain variable region comprising an HCDR1 amino acid sequence of SEQ ID NO: 30, an HCDR2 amino acid sequence of SEQ ID NO: 32, and an HCDR3 amino acid sequence of SEQ ID NO: 34; and
(ii) an immunoglobulin light chain variable region comprising an LCDR1 amino acid sequence of SEQ ID NO: 42, an LCDR2 amino acid sequence of SEQ ID NO: 10, and an LCDR3 amino acid sequence of SEQ ID NO: 36.